Trial Profile
Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFα Antagonist
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gerilimzumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bird Rock Bio
- 09 Jul 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 16 Jan 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.